DrugPatentWatch Database Preview

Belinostat - Generic Drug Details

see a sample report or, see our see our flat-rate plans

What are the generic sources for belinostat and what is the scope of belinostat patent protection?

Belinostat is the generic ingredient in one branded drug marketed by Spectrum Pharms and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Belinostat has fifty-nine patent family members in twenty-seven countries.

There are five drug master file entries for belinostat. One supplier is listed for this compound.

Summary for belinostat

International Patents:	59
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	5
Suppliers / Packagers:	1
Bulk Api Vendors:	76
Clinical Trials:	41
Patent Applications:	19
DailyMed Link:	belinostat at DailyMed

Pharmacology for belinostat

Drug Class	Histone Deacetylase Inhibitor
Mechanism of Action	Histone Deacetylase Inhibitors

Synonyms for belinostat

(2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]acrylamide
(2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
(E)-3-[3-(phenylsulfamoyl)phenyl]prop-2-enehydroxamic acid
(E)-N-hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide
(E)-N-Hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide
(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
2-Propenamide, N-hydroxy-3-(3-((phenylamino)sulfonyl)phenyl)-
2-Propenamide, N-hydroxy-3-(3-((phenylamino)sulfonyl)phenyl)-, (2E)-
2-Propenamide, N-hydroxy-3-[3-[(phenylamino)sulfonyl]phenyl]-, (2E)-
2-Propenamide,N-hydroxy-3-[3-[(phenylamino)sulfonyl]phenyl]-,(2E)-
414864-00-9
5OG
866323-14-0
866323-14-0 (E Isomer)
A25012
AB0007889
ABP000140
AC-25046
AKOS025401741
AN-1073
AOB87787
API0003555
AS-17068
AX8144528
BC251660
BCP9000386
BCPP000351
BDBM25150
Beleodaq
Beleodaq (TN)
Belinostat (PXD101)
Belinostat - PXD101
Belinostat (PXD101)
Belinostat [USAN:INN]
Belinostat Ph3
Belinostat,PXD101, PX105684
Belinostat/PXD101,PX105684/
BRD-K17743125-001-01-9
CCG-208758
CHEBI:61076
CHEBI:94531
D0XT6W
DB05015
DTXSID60194378
E-Belinostat
EX-A180
F4H96P17NZ
GTPL7496
J-523584
KB-74881
LS41098
MFCD08064035
MLS006011091
MolPort-009-679-433
N-Hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide
N-hydroxy-3-(3-(phenylsulfamoyl)phenyl)prop-2-enamide
N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide
N-HYDROXY-3-(3-PHENYLSULFAMOYLPHENYL)ACRYLAMIDE
N-Hydroxy-3-(3-phenylsulphamoylphenyl)acrylamide
N-Hydroxy-3-[(phenylamino)sulfonyl]-trans-cinnamamide
N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]-2-propenamide
N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PR
N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PROPENAMIDE
NCNRHFGMJRPRSK-MDZDMXLPSA-N
NSC-726630
NSC726630
OR190689
PDX-101
PDX101
PubChem22405
PX 105684
PX-105684
PX105684
PX105684, 414864-00-9
PXD 101
PXD-101
PXD101
QCR-181
RL03602
RT-014445
s1085
SC-71101
SMR004702879
UNII-F4H96P17NZ
W-5363
ZINC3818726

US Patents and Regulatory Information for belinostat

+ Get email alerts for changes to this table

Glossary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Spectrum Pharms	BELEODAQ	belinostat	POWDER;INTRAVENOUS	206256-001	Jul 3, 2014		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y			➤ Sign Up
Spectrum Pharms	BELEODAQ	belinostat	POWDER;INTRAVENOUS	206256-001	Jul 3, 2014		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				➤ Sign Up
Spectrum Pharms	BELEODAQ	belinostat	POWDER;INTRAVENOUS	206256-001	Jul 3, 2014		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for belinostat

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
7,183,298	Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors	➤ Sign Up
7,407,988	Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors	➤ Sign Up
7,557,140	Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration